Endocan Corp
Thermic Sciences International develops and sells hemp based products. The company offers hemp formulation-based health and wellness solutions, as well as cosmeceuticals, nutraceuticals, and food brands. It also provides over the counter products for hair and skin include Hempery miracle oil, a skin care solution; Hemp milk body wash, a creamy soap; Hemp lotion bars for moisturizing hands and bod… Read more
Endocan Corp (ENDO) - Net Assets
Latest net assets as of March 2013: $-1.49 Million USD
Based on the latest financial reports, Endocan Corp (ENDO) has net assets worth $-1.49 Million USD as of March 2013.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($59.00) and total liabilities ($1.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.49 Million |
| % of Total Assets | -2531896.61% |
| Annual Growth Rate | N/A |
| 5-Year Change | -528.99% |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Endocan Corp - Net Assets Trend (2000–2012)
This chart illustrates how Endocan Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Endocan Corp (2000–2012)
The table below shows the annual net assets of Endocan Corp from 2000 to 2012.
| Year | Net Assets | Change |
|---|---|---|
| 2012-12-31 | $-1.50 Million | -146.98% |
| 2010-12-31 | $-607.10K | +42.88% |
| 2009-12-31 | $-1.06 Million | -49.36% |
| 2008-12-31 | $-711.55K | -303.58% |
| 2007-12-31 | $349.52K | +139.91% |
| 2006-12-31 | $-875.68K | -312.02% |
| 2005-12-31 | $-212.53K | -41410.55% |
| 2004-12-31 | $-512.00 | +96.65% |
| 2000-12-31 | $-15.26K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Endocan Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2891371300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2012)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $52.79K | % |
| Other Components | $27.94 Million | % |
| Total Equity | $-1.50 Million | 100.00% |
Endocan Corp Competitors by Market Cap
The table below lists competitors of Endocan Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Baltic International USA Inc
PINK:BISA
|
$3.29K |
|
CGS International Inc
PINK:CGSI
|
$3.29K |
|
Ellies
JSE:ELI
|
$3.30K |
|
Tan Delta Systems PLC
LSE:TAND
|
$3.30K |
|
ROMIOS GOLD RES
MU:D4R
|
$3.29K |
|
FINCORP INVESTMENT LTD
SEM:FINC
|
$3.29K |
|
Vintage Wine Estates, Inc.
PINK:VWESQ
|
$3.28K |
|
Beyon 3D Ltd
TA:BYON
|
$3.28K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Endocan Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2011 to 2012, total equity changed from -1,235,159 to -1,499,411, a change of -264,252.
- Net loss of 3,311,384 reduced equity.
- Share repurchases of 137,611 reduced equity.
- Other factors increased equity by 3,184,743.
Equity Change Factors (2011 to 2012)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.31 Million | -220.85% |
| Share Repurchases | $137.61K | -9.18% |
| Other Changes | $3.18 Million | +212.4% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Endocan Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $-0.01 | $0.00 | x |
| 2001-12-31 | $-0.02 | $0.00 | x |
| 2002-12-31 | $-0.22 | $0.00 | x |
| 2003-12-31 | $0.00 | $0.00 | x |
| 2004-12-31 | $0.00 | $0.00 | x |
| 2005-12-31 | $-0.20 | $0.00 | x |
| 2006-12-31 | $-0.64 | $0.00 | x |
| 2007-12-31 | $0.23 | $0.00 | x |
| 2008-12-31 | $-0.33 | $0.00 | x |
| 2009-12-31 | $-0.20 | $0.00 | x |
| 2010-12-31 | $-0.09 | $0.00 | x |
| 2011-12-31 | $-0.07 | $0.00 | x |
| 2012-12-31 | $-0.05 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Endocan Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-70.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 0.00% | -18026200.00% | 0.00x | 0.00x | $-178.74K |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.67K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.58 Million |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.81K |
| 2004 | 0.00% | -197.18% | 0.90x | 0.00x | $-73.77K |
| 2005 | 0.00% | -87.88% | 7.16x | 0.00x | $-342.75K |
| 2006 | 0.00% | -187.79% | 2.34x | 0.00x | $-2.03 Million |
| 2007 | -915.53% | -196.68% | 1.07x | 4.36x | $-3.23 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.04 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-246.72K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.24 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.86 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.16 Million |
Industry Comparison
This section compares Endocan Corp's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $7,181,833,981
- Average return on equity (ROE) among peers: 7.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Endocan Corp (ENDO) | $-1.49 Million | 0.00% | N/A | $3.29K |
| AirBoss of America Corp (ABSSF) | $197.00 Million | -16.19% | 1.24x | $57.06 Million |
| Asia Carbon Industries Inc (ACRB) | $19.13 Million | 17.11% | 0.33x | $0.98 |
| Aimia Inc (AIMFF) | $1.29 Billion | -4.63% | 2.83x | $103.68 Million |
| L'Air Liquide S.A (AIQUF) | $11.83 Billion | 14.08% | 1.26x | $107.70 Billion |
| Akzo Nobel N.V (AKZOF) | $7.58 Billion | 14.03% | 1.29x | $9.73 Billion |
| Albemarle Corp (ALB) | $545.00 Million | 9.41% | 1.09x | $19.53 Billion |
| ALPEK S.A.B. de C.V (ALPKF) | $49.59 Billion | 15.64% | 1.50x | $214.40 Million |
| Altech Batteries Limited (ALTHF) | $97.54 Million | -5.87% | 0.01x | $27.89 Million |
| Arcadium Lithium plc (ALTM) | $333.00 Million | 14.14% | 0.12x | $6.26 Billion |
| Alto Ingredients Inc (ALTO) | $345.21 Million | 13.35% | 0.40x | $212.84 Million |